Breast Cancer

As additional antibody-drug conjugates continue to emerge for the treatment of patients with HER2-negative breast cancer, identifying optimal sequencing strategies and managing toxicities associated with these agents remain top priorities for their use, according to Hope S. Rugo, MD.

Kelly K. Hunt, MD, FACS, FSSO, discusses technical considerations for axillary reverse mapping in breast cancer for the reduction or prevention of lymphedema.

The FDA approved an expanded indication for abemaciclib (Verzenio) in combination with endocrine therapy for the adjuvant treatment of adult patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer that is at a high risk of recurrence.

With the advent of effective drug regimens to treat HER2-positive breast cancer, the use of tailored efforts with neoadjuvant therapy in this space may continue to improve efficacy moving forward.

The advent of antibody-drug conjugates has placed a renewed focus on the lesser thought of HER2 classifications of IHC 1+ and 0.

Melissa L. Pilewskie, MD, highlightes some of the primary components of her presentation concerning high-risk breast lesions, which will be delivered during the 40th Annual Miami Breast Cancer Conference®

Laura J. Esserman, MD, MBA, discusses the rationale and design for the phase 2 I-SPY2 trial.

The agenda set for this year's Miami Breast Cancer Conference® has been shaped by the recent updates out of the 2022 San Antonio Breast Cancer Symposium, updates to guideline recommendations over the past year, and the influence of new indications and approvals across subtypes of breast cancer.

Paolo Tarantino, MD, highlights additional abstracts from SABCS 2022 that he found particularly interesting.

Komal Jhaveri, MD, FACP, explains the potential role ADCs may have in the future of breast cancer treatment.

Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.

A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.

Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.

Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.

Yen-Shen Lu, MD, PhD, discusses the primary results of the RIGHT Choice trial and what they could mean for the use of ribociclib and endocrine therapy in this population.

Maryam Lustberg, MD, MPH introduces the standard of care regimens for the second-line treatment of HER2+ metastatic breast cancer, followed by a discussion of recent data on the ADC trastuzumab deruxtecan (T-DXd).

Dr Debu Tripathy explains the treatment options for patients with HER2+ metastatic breast cancer in the third-line and later-line settings, including combination tucatinib/trastuzumab/capecitabine.

Heather Lynn McArthur, MD, MPH, discusses the implications of the phase 3 ASCENT trial in patients with advanced triple-negative breast cancer.

The combination of the targeted immunotherapy Bria-IMT and retifanlimab demonstrated signs of clinical benefit and was found to be well tolerated in patients with advanced metastatic breast cancer.

Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.

Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.

Virginia Kaklamani, MD, discusses how racial disparities may affect patient outcomes and treatment expectations based on data from the RxPONDER trial in breast cancer.

M. Michele Blackwood, MD, FACS, discusses the implementation of the phase 2 I-SPY 2 trial in breast cancer at Robert Wood Johnson Medical Center.

Dr Jhaveri explains her thoughts on sequencing ADCs in the treatment of triple-negative breast cancer.

Drs Jhaveri and Tarantino discuss the standard of practice for managing triple negative breast cancer.